Resverlogix Corp. (TSE:RVX – Get Free Report)’s share price reached a new 52-week low on Thursday. The stock traded as low as C$0.09 and last traded at C$0.09, with a volume of 23,300 shares changing hands. The stock had previously closed at C$0.08.
Resverlogix Stock Performance
The company has a current ratio of 0.04, a quick ratio of 0.04 and a debt-to-equity ratio of -82.47. The stock’s 50 day moving average is C$0.09 and its 200 day moving average is C$0.10. The stock has a market capitalization of C$29.26 million, a price-to-earnings ratio of -2.12 and a beta of -0.11.
About Resverlogix
Founded in 2001, Resverlogix is a Calgary based late-stage biotechnology company, and a world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease. Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. We aim to improve patients’ lives by restoring biological functions – altered by serious illnesses such as cardiovascular disease – back to a healthier state.
Further Reading
- Five stocks we like better than Resverlogix
- Is Texas Instruments Setting Up for Its Next Big Breakout?
- Pegasystems’ Q3 Miss Exposed the Problem Standing Between AI and Cash Flow
- Lam Research’s Earnings Beat Wasn’t the Real Story—Its 2027 Outlook Was
- Tesla’s Flying-Car Hype Hits an Earnings Reality Check
Receive News & Ratings for Resverlogix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix and related companies with MarketBeat.com's FREE daily email newsletter.
